Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer

Carlos Acevedo-Gadea; Alessandro D. Santin; Susan A. Higgins; Shweta Urva; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Thomas Rutherford; Peter E. Schwartz; Maysa M. Abu-Khalaf

doi:10.1097/IGC.0000000000000085

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Uterine Cancer

Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Acevedo-Gadea C, Santin AD, Higgins SA, et al

Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer

International Journal of Gynecologic Cancer 2014;24:528-533.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password